160 / 1498
7-year OS 86% in control arm compared with 89% in the
90
Y-ibritumomab arm
HR = 1.50 (95% CI: 0.84 – 2.68);
P
= 0.478
90
Y-ibritumomab
Control
At risk:
207
202
200
192
178
175
166
152
47
45
0
25
50
75
100
0
21
42
63
84
Cumulative Percentage
90
Y-ibritumomab: n = 207
Median OS: > 110 mo
Control: n = 202
Median OS: > 113 mo
Overall Survival for Treatment Groups
90
Y-ibritumomab
Control
207
202
22
26
N F
OS From Time of Randomization (months)